A non-biodegradable intra-ocular implant delivering timolol to treat glaucoma for
minimum 2 years.
A non-biodegradable intra-ocular implant delivering precise controlled dose of two Active Pharmaceuticals Ingredients (APIs) in the eye.
A biodegradable short-term implant, based on well-known drugs, to prevent inflammation and pain after eye surgery.
Our team aims to leverage on EyeD Pharma’s proprietary technological platform to enhance our product portfolio in line with our corporate strategy, either on a standalone basis or through dedicated partnerships, from the idea to the market.
Our teams are indeed able, on the basis of clinical unmet needs identified by clinicians or industrial partners, to provide a full development approach for an implant releasing drug product candidate including formulation, non-clinical and clinical project management, Regulatory Affairs, Market Access Strategy, Manufacturing and industrialization, thanks to Unid Manufacturing, our fully owned CDMO located near Liège, Belgium.
Average age
Innovation StaffAll our product candidates aim to enhance patient quality of life and are based on clinical unmet need identified by internationally renowned KOL’s
We manage all the expertise and processes, from the idea to the market
Creation of high-quality long-term employment and significant contribution to the economic redeployment of Wallonia. Eyed’s team is today composed of 66 FTEs
Our technological platform allows to give access to long term innovative ophthalmological treatments to developing countries populations, where glaucoma is the second cause of blindness
